We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2B
1-Year Est. Return 444.09%
This Fund
S&P 500
This Quarter Est. Return
+70.52%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$500M
AUM Growth
+$238M
Cap. Flow
+$166M
Cap. Flow %
33.16%
Top 10 Hldgs %
50.21%
Holding
73
New
32
Increased
7
Reduced
5
Closed
27

Top Buys

Rank Stock Value
1
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
+$55.5M
2
RNAM
Avidity Biosciences
RNAM
+$26.7M
3
RPTX
Repare Therapeutics
RPTX
+$21.4M
4
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$17.9M
5
AMTI
Applied Molecular Transport Inc. Common Stock
AMTI
+$16.8M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$20.2M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$18.3M
3
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$14.1M
4
MRNA icon
Moderna
MRNA
+$13.8M
5
ASND icon
Ascendis Pharma A/S
ASND
+$13.5M

Sector Composition

Rank Sector Weight
1 Healthcare 94.66%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GBIO
26
DELISTED
Generation Bio
GBIO
$6.83M 1.36%
+32,500
New +$7.24M
KALV
27
DELISTED
KalVista Pharmaceuticals
KALV
$6.81M 1.36%
+562,900
New +$5.99M
IGMS
28
DELISTED
IGM Biosciences
IGMS
$6.7M 1.34%
91,841
-82,024
-47% -$4.98M
BLU
29
DELISTED
BELLUS Health Inc.
BLU
$6.17M 1.23%
600,000
-175,377
-23% -$1.78M
ETNB
30
DELISTED
89bio
ETNB
$5.78M 1.16%
290,000
+43,000
+17% +$1.05M
APTO
31
DELISTED
Aptose Biosciences, Inc.
APTO
$4.73M 0.95%
+1,667
New +$5.38M
BDTX icon
32
Black Diamond Therapeutics
BDTX
$102M
$4.68M 0.94%
123,465
– –
SWTX
33
DELISTED
SpringWorks Therapeutics
SWTX
$4.62M 0.92%
+110,000
New +$3.91M
ISEE
34
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$4.59M 0.92%
+900,000
New +$3.75M
RAPT
35
DELISTED
RAPT Therapeutics
RAPT
$4.5M 0.9%
+19,375
New +$3M
LSACU
36
DELISTED
LifeSci Acquisition Corp. Unit 1 COM & 1 WT
LSACU
$4.4M 0.88%
400,000
– –
RCKT icon
37
Rocket Pharmaceuticals
RCKT
$361M
$3.14M 0.63%
150,000
+134,191
+849% +$2.42M
STRO icon
38
Sutro Biopharma
STRO
$392M
$2.81M 0.56%
+36,195
New +$3.47M
FUSN
39
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$2.12M 0.42%
+121,128
New +$2.11M
CHAQ.U
40
DELISTED
Chardan Healthcare Acquisition 2 Corp. Units, each consisting of one share of Common Stock, and one
CHAQ.U
$2.1M 0.42%
+200,000
New +$2.01M
XFOR icon
41
X4 Pharmaceuticals
XFOR
$370M
$1.48M 0.3%
+5,283
New +$1.45M
ARYBU
42
DELISTED
ARYA Sciences Acquisition Corp II Unit
ARYBU
$1.16M 0.23%
+100,000
New +$1.1M
LUMO
43
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$825K 0.16%
+50,000
New +$595K
LRMR icon
44
Larimar Therapeutics
LRMR
$398M
$739K 0.15%
+57,475
New +$669K
MREO
45
Mereo BioPharma
MREO
$49M
$612K 0.12%
+200,000
New +$353K
APLT
46
DELISTED
Applied Therapeutics
APLT
$455K 0.09%
+12,600
New +$527K
ABBV icon
47
AbbVie
ABBV
$458B
– –
-265,600
Closed -$20.2M
ALNY icon
48
Alnylam Pharmaceuticals
ALNY
$37.7B
– –
-39,644
Closed -$4.32M
ASND icon
49
Ascendis Pharma A/S
ASND
$16.8B
– –
-120,000
Closed -$13.5M
BMY icon
50
Bristol-Myers Squibb
BMY
$128B
– –
-194,500
Closed -$10.8M
1
2
3

Similar funds

MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Logos Global Management's Q2 2020 Portfolio in Review

As of Q2 2020, Logos Global Management held 73 positions worth $500M, up 90% from $263M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Logos Global Management deployed $166M of net new capital in Q2 2020, opening 32 new positions and adding to 7 existing holdings. Its largest new stake was Forma Therapeutics Holdings, Inc. Common Stock: 1,280,000 shares worth $59.5M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 93% a quarter earlier.

On the sell side, the largest reduction was Passage Bio, an estimated $5.82M trimmed.

  • Logos Global Management's largest Q2 2020 buy was Forma Therapeutics Holdings, Inc. Common Stock: 1,280,000 shares worth $59.5M.
  • Logos Global Management added most to Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2020, an estimated $17.9M increase.
  • Logos Global Management's biggest Q2 2020 reduction was Passage Bio, cutting an estimated $5.82M.
  • Logos Global Management fully exited AbbVie in Q2 2020, selling an estimated $20.2M.
  • Logos Global Management's ten largest holdings make up 50% of its $500M portfolio in Q2 2020.
  • Logos Global Management opened 32 new positions and closed 27 in Q2 2020.
  • Logos Global Management's portfolio value rose 90% quarter-over-quarter to $500M.

Based on Logos Global Management's 13F filing for Q2 2020, filed 14 Aug 2020.